Profound Ai by iCAD for Senographe Pristina

NEW! ProFound AI 3.0 with increased performance

Compared to the previous version³, the third generation Profound AI offers up to 7% improvement in specificity on Senographe Pristina DBT images while maintaining sensitivity performance. Profound AI 3.0 also delivers up to 40% faster processing.

Clinical image gallery

Invasive Ductal Carcinoma

Case scores are integrated to the worklist
Markers help identify microcalcifications, masses and architectural distortions.
Seamless integration on Seno Iris™ SP3

Profound-AI_Fullwidth_Video_Screen_Capture

Featured products

ABUS Breast Imaging

GE Healthcare offers the first FDA-approved ultrasound supplemental technology that is specifically designed for detecting cancer in dense breast tissue. Compared to mammography alone, Invenia ABUS 2.0 imaging looks differently at dense breast tissue, providing a comprehensive view of the breast.

Breast Cancer

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year. According to the WHO, it is estimated that 627,000 women died from breast cancer in 2018 which represents 15 percent of all cancer deaths among women.¹

Compared to reading without ProFound AI. iCAD labelling and user manual, DTM163 rev B.
Reading times may vary based on the specific functionality of the viewing application used for interpretation.
iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor

JB00659XU

NEW! ProFound AI 3.0 with increased performance

Clinical image gallery

Invasive Ductal Carcinoma

Case scores are integrated to the worklist

Markers help identify microcalcifications, masses and architectural distortions.

Seamless integration on Seno Iris™ SP3

Featured products

ABUS Breast Imaging

Breast Cancer